Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's business development and clinical development plans for liarozole, and the potential therapeutic benefits of RAMBAs in general and liarozole in particular. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier's products, Barrier's ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2007 which is on file
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm ... Lawsuits (case #59776/2014), announces they have launched a new ... the popular hair dye, Just For Men, has caused some ... and other areas. In addition to detailing symptoms that are ... the advertisements being run by Wright & Schulte LLC will ...
(Date:7/12/2014)... Beach, FL (PRWEB) July 12, 2014 ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of ... 2014 Quinceanera dresses . The company’s new items ... fashionable without paying a large amount of money. They ... off. , The company’s online shop has become a ... occasion outfits. In addition to exquisite Quinceanera dresses, it ...
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
Breaking Medicine News(10 mins):Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2
... commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) is so potent. ... University School of Medicine, is reported online today by ... the July 2 print issue. ,It had ... cells in the intestine from absorbing cholesterol. The new ...
... Louis researchers have identified common DNA variations that ... of the eight genetic alterations the scientists identified ... vaccination. A few, however, reduced fever risk. ... same genetic variations linked to fever following smallpox ...
... to scientist at annual conference of the European Society ... abnormal can undergo chromosomal modifications. , ... Maternity Hospital, Tel Aviv Sourasky Medical Centre, Tel Aviv, ... meant that the results of preimplantation genetic screening (PGS) ...
... For many decades, medical research studies focused primarily on ... applied to women. But we now know that the ... women are more than skin deep. Beginning in 1990, ... based advocacy organization, conveyed to a national audience the ...
... and their friends filled the area in and around the ... 14th annual Komen Puget Sound Race for the Cure . ... cancer, while many others were running to honor family members ... in the pink T-shirts and sporting the medallions awarded by ...
... much as $2.7 billion a year, according to the Access ... of Crohn's disease and ulcerative colitis. Crohn's disease is a ... ulcerations (breaks in the lining) of the small and large ... mouth to the anus. It is named after the physician ...
Cached Medicine News:Health News:Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 3Health News:Preimplanted Genetic Screening Should Be Interpreted With Caution 2Health News:Rare Womens Lung Disease May Yield Insights Into Common Diseases 2Health News:Annual Cancer Run Draws Huge Response in US 2Health News:Inflamed Intestines Cost Australians Heavily 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: